



US010369109B2

**(12) United States Patent**  
**Bartholomaeus et al.****(10) Patent No.: US 10,369,109 B2****(45) Date of Patent: \*Aug. 6, 2019****(54) ABUSE-PROOFED DOSAGE FORM****(71) Applicant: GRÜNENTHAL GMBH, Aachen (DE)****(72) Inventors: Johannes Bartholomaeus, Aachen (DE); Heinrich Kugelmann, Aachen (DE)****(73) Assignee: GRÜNENTHAL GMBH, Aachen (DE)****(\*) Notice:** Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

**(21) Appl. No.: 16/032,533****(22) Filed: Jul. 11, 2018****(65) Prior Publication Data**

US 2018/0318223 A1 Nov. 8, 2018

**Related U.S. Application Data****(63)** Continuation of application No. 15/587,501, filed on May 5, 2017, now abandoned, which is a continuation of application No. 15/245,424, filed on Aug. 24, 2016, now Pat. No. 9,675,610, which is a continuation of application No. 14/527,911, filed on Oct. 30, 2014, now abandoned, which is a continuation of application No. 14/069,439, filed on Nov. 1, 2013, now abandoned, which is a continuation of application No. 13/803,789, filed on Mar. 14, 2013, now abandoned, which is a continuation of application No. 13/572,926, filed on Aug. 13, 2012, now abandoned, which is a continuation of application No. 13/365,742, filed on Feb. 3, 2012, now abandoned, which is a continuation of application No. 12/822,719, filed on Jun. 24, 2010, now abandoned, which is a continuation of application No. 11/007,887, filed on Dec. 9, 2004, now Pat. No. 7,776,314, which is a continuation of application No. PCT/EP03/06314, filed on Jun. 16, 2003.**(30) Foreign Application Priority Data**Jun. 17, 2002 (DE) ..... 102 27 077  
Oct. 25, 2002 (DE) ..... 102 50 083**(51) Int. Cl.****A61K 31/485** (2006.01)  
**A61K 9/20** (2006.01)  
**A61K 9/48** (2006.01)  
**A61K 31/137** (2006.01)  
**A61K 31/5513** (2006.01)  
**A61K 45/06** (2006.01)  
**A61K 47/38** (2006.01)  
**A61K 9/00** (2006.01)**(52) U.S. Cl.**CPC ..... **A61K 9/2054** (2013.01); **A61K 9/0053** (2013.01); **A61K 9/205** (2013.01); **A61K 9/2009** (2013.01); **A61K 9/2013** (2013.01);**A61K 9/4866** (2013.01); **A61K 31/137** (2013.01); **A61K 31/485** (2013.01); **A61K 31/5513** (2013.01); **A61K 45/06** (2013.01); **A61K 47/38** (2013.01)**(58) Field of Classification Search**

None

See application file for complete search history.

**(56) References Cited**

## U.S. PATENT DOCUMENTS

2,524,855 A 10/1950 Schnider et al.  
2,806,033 A 9/1957 Lewenstein et al.  
2,987,445 A 6/1961 Levesque  
3,332,950 A 7/1967 Blumberg et al.  
3,370,035 A 2/1968 Ogura et al.  
3,652,589 A 3/1972 Flick et al.  
3,658,259 A 4/1972 Ledergerber et al.  
3,806,603 A 4/1974 Gaunt et al.  
3,865,108 A 2/1975 Hartop  
3,941,865 A 3/1976 Miller et al.  
3,966,747 A 6/1976 Monkovic et al.  
3,980,766 A 9/1976 Shaw et al.  
4,002,173 A 1/1977 Manning et al.  
4,014,965 A 3/1977 Stube et al.  
4,070,494 A 1/1978 Hoffmeister et al.  
4,070,497 A 1/1978 Wismer et al.  
4,175,119 A 11/1979 Porter  
4,200,704 A 4/1980 Stanley et al.

(Continued)

## FOREIGN PATENT DOCUMENTS

AR 046994 A1 12/2004  
AR 045353 A1 10/2005

(Continued)

## OTHER PUBLICATIONS

2.9 Methoden der pharmazeutischen Technologie, European Pharmacopeia, 143-144, 1997, (Full English translation attached).

Albertini, B. "New spray congealing atomizer for the microencapsulation of highly concentrated solid and liquid substances" European Journal of Pharmaceutics and Biopharmaceutics 69 (2008) 348-357.

Alekseeva et al, Chemical-Pharmaceutical Journal, vol. 41, No. 9, 2007, 49-52. (Full translation attached.).

Almeida, A. et al., Ethylene vinyl acetate as matrix for oral sustained release dosage forms produced via hot-melt extrusion, European Journal of Pharmaceutics and Biopharmaceutics 77 (2011) 297-305.

(Continued)

Primary Examiner — Jessica Worsham

**(74) Attorney, Agent, or Firm** — Norris McLaughlin, P.A.**(57) ABSTRACT**

A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid.

**28 Claims, No Drawings**